ES2179473T3 - Composiciones que contienen capsaicina o analogos de capsaicina y un anestesico local. - Google Patents

Composiciones que contienen capsaicina o analogos de capsaicina y un anestesico local.

Info

Publication number
ES2179473T3
ES2179473T3 ES98911614T ES98911614T ES2179473T3 ES 2179473 T3 ES2179473 T3 ES 2179473T3 ES 98911614 T ES98911614 T ES 98911614T ES 98911614 T ES98911614 T ES 98911614T ES 2179473 T3 ES2179473 T3 ES 2179473T3
Authority
ES
Spain
Prior art keywords
capsaicin
site
anesthesia
pain
capsaicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98911614T
Other languages
English (en)
Other versions
ES2179473T5 (es
Inventor
James N Campbell
Marco Pappagallo
Richard A Meyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21912426&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2179473(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2179473T3 publication Critical patent/ES2179473T3/es
Publication of ES2179473T5 publication Critical patent/ES2179473T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a procedimientos y composiciones destinada al tratamiento del dolor en una zona específica, con una concentración efectiva de capsaicina o de análogos de capsaicina. Los procedimientos consisten en anestesiar la zona donde la capsaicina o los derivados de capsaicina deben ser administrados, y en administrar una concentración efectiva de capsaicina en la articulación. Se puede anestesiar directamente la zona en cuestión o una zona a distancia de donde la anestesia puede alcanzar la zona de administración de la capsaicina. Por ejemplo, se puede efectuar una anestesia de la región epidural en los pacientes a quienes la capsaicina debe ser administrada en una zona situada en la parte inferior del cuerpo a partir de la dimensión. Al efectuar un tratamiento previo de la zona con un anestésico, se puede utilizar una concentración sensiblemente más elevada de capsaicina. Las concentraciones efectivas de capsaicina o de análogos de capsaicina están comprendidos entre 0,01 y 10% en peso, preferentemente entre 1 y 7,5% en peso, y son idealmente de aproximadamente un 5% en peso. Así, se puede aliviar mejor y de manera prolongada un dolo durante periodos que van de una a varias semanas. En ciertos casos, la suspensión del dolor puede ser más importante porque la afección que provoca el dolor puede conocer una mejora en razón de varios factores, en particular un mejor tratamiento físico gracias al reducción del dolor en los tejidos blandos, los que puede favorecer una mejor movilización de los tejidos blandos, tendones y articulaciones.
ES98911614T 1997-03-13 1998-03-12 Composiciones que contienen capsaicina o analogos de capsaicina y un anestesico local. Expired - Lifetime ES2179473T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4069797P 1997-03-13 1997-03-13
US40697P 1997-03-13

Publications (2)

Publication Number Publication Date
ES2179473T3 true ES2179473T3 (es) 2003-01-16
ES2179473T5 ES2179473T5 (es) 2006-03-01

Family

ID=21912426

Family Applications (2)

Application Number Title Priority Date Filing Date
ES01204692T Expired - Lifetime ES2350755T3 (es) 1997-03-13 1998-03-12 Composiciones que contienen capsaicina o análogos de capsaicina y un anestésico local.
ES98911614T Expired - Lifetime ES2179473T5 (es) 1997-03-13 1998-03-12 Composiciones que contienen capsaicina o analogos de capsaicina y un anestesico local.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES01204692T Expired - Lifetime ES2350755T3 (es) 1997-03-13 1998-03-12 Composiciones que contienen capsaicina o análogos de capsaicina y un anestésico local.

Country Status (12)

Country Link
US (1) US5962532A (es)
EP (2) EP1201241B8 (es)
JP (1) JP2001515492A (es)
AT (2) ATE481970T1 (es)
AU (1) AU720859B2 (es)
CA (1) CA2285203C (es)
DE (2) DE69841907D1 (es)
DK (2) DK0998288T4 (es)
ES (2) ES2350755T3 (es)
HK (1) HK1027759A1 (es)
PT (2) PT1201241E (es)
WO (1) WO1998040070A1 (es)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248788B1 (en) 1996-11-06 2001-06-19 The Regents Of The University Of California Therapeutic method with capsaicin and capasicin analogs
US6239180B1 (en) * 1995-11-08 2001-05-29 The Regents Of The University Of California Transdermal therapeutic device and method with capsaicin and capsaicin analogs
ES2343767T3 (es) 1997-09-18 2010-08-09 Pacira Pharmaceuticals, Inc. Composiciones anestesicas liposomicas de liberacion sostenida.
WO1999025319A1 (en) 1997-11-14 1999-05-27 Depotech Corporation Production of multivesicular liposomes
SE9800139D0 (sv) * 1998-01-21 1998-01-21 Astra Ab New use
US6790207B2 (en) 1998-06-04 2004-09-14 Curon Medical, Inc. Systems and methods for applying a selected treatment agent into contact with tissue to treat disorders of the gastrointestinal tract
US6802841B2 (en) 1998-06-04 2004-10-12 Curon Medical, Inc. Systems and methods for applying a selected treatment agent into contact with tissue to treat sphincter dysfunction
CA2338031C (en) 1998-07-17 2006-12-05 Sankaram Bhima Mantripragada Biodegradable compositions for the controlled release of encapsulated substances
AU8066701A (en) * 2000-07-20 2002-02-05 Neurogen Corp Capsaicin receptor ligands
US20040146590A1 (en) 2001-03-22 2004-07-29 Iadarola Michael J Molecular neurochirurgie for pain control administering locally capsaicin or resinferatoxin
CA2447990C (en) * 2001-05-31 2012-01-31 Skyepharma Inc. Encapsulation of nanosuspensions in liposomes and microspheres
JP2005507865A (ja) * 2001-08-10 2005-03-24 シンタ ファーマシューティカルズ コーポレーション カヴァラクトン組成物および使用法
US20030125347A1 (en) * 2001-11-02 2003-07-03 Elan Corporation Plc Pharmaceutical composition
WO2003062209A2 (en) * 2002-01-17 2003-07-31 Neurogen Corporation Substituted quinazolin-4-ylamine analogues as modulators of capsaicin
EP1539124B1 (en) * 2002-09-05 2018-07-18 Vanderbilt Royalty Sub L.P. Compositions and kits for the removal of irritating compounds from bodily surfaces
EP1551402A4 (en) * 2002-09-23 2009-05-27 Verion Inc PHARMACEUTICAL COMPOSITIONS NOT INDUCING ABUSE
US20050020690A1 (en) 2002-12-18 2005-01-27 Algorx Infiltration of capsaicin into surgical sites and open wounds
US20040191338A1 (en) * 2002-12-18 2004-09-30 Algorx Administration of capsaicinoids
EP1610742B1 (en) * 2003-04-10 2015-01-21 Neurogesx, Inc. Uses and compositions for administration of capsaicin
CA2569155A1 (en) 2004-06-02 2005-12-15 Sri International Formulations comprising a capsaicinoid a local anesthetic and/or an antipruritic agent for the treatment of pain
EP1830836B1 (de) 2004-12-22 2010-11-24 Mestex AG Mischung eines vanilloidrezeptoragonisten mit einer nervenregenerationshemmenden substanz, ihre verwendung für die herstellung eines schmerzmittels und verfahren zur applikation dieses mittels
CA2594203C (en) * 2004-12-28 2014-04-29 Mestex Ag Use of a vanilloid receptor agonist together with a glycosaminoglycan or proteoglycan for producing an agent for treating articular pain and method for applying said agent
ES2533256T3 (es) 2004-12-28 2015-04-08 Mestex Ag Uso de resiniferatoxina (RTX) para la fabricación de un medicamento para el tratamiento del dolor
US20060204561A1 (en) * 2005-02-14 2006-09-14 Naweed Muhammad Device for delivery of TRPV1 agonists
EP1865933B1 (en) * 2005-03-30 2015-11-04 Vanderbilt Royalty Sub L.P. Low-concentration capsaicin patch and methods for treating neuropathic pain
WO2006107723A1 (en) * 2005-04-01 2006-10-12 Neurogesx, Inc. Oils of capsaicinoids and methods of making and using the same
US8916611B2 (en) * 2006-04-28 2014-12-23 Warsaw Orthopedic, Inc. Pharmaceutical removal of neuronal extensions from a degenerating disc
US7943666B2 (en) * 2006-07-24 2011-05-17 Trinity Laboratories, Inc. Esters of capsaicin for treating pain
US7645767B2 (en) * 2006-08-31 2010-01-12 Trinity Laboratories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
EP2276420B1 (en) 2008-04-04 2021-10-06 Journey1, Inc. Device to treat an eye having an epithelium with a defect
US8158682B2 (en) * 2008-09-12 2012-04-17 Vallinex, Inc. Instillation administration of capsaicinoids for the treatment of pain
US8987328B2 (en) * 2008-10-30 2015-03-24 Trinity Laboratories, Inc. Esters of capsaicinoids as dietary supplements
CA2761156C (en) * 2009-05-07 2017-03-14 University Of Cincinnati Methods of preventing ischemic injury using peripheral nociceptive stimulation
US20110135627A1 (en) * 2009-10-07 2011-06-09 The Inflasoothe Group, Inc. Pain relief composition, system and method
US8591025B1 (en) 2012-09-11 2013-11-26 Nexisvision, Inc. Eye covering and refractive correction methods for LASIK and other applications
US9498385B2 (en) 2009-10-23 2016-11-22 Nexisvision, Inc. Conformable therapeutic shield for vision and pain
NO2490635T3 (es) 2009-10-23 2018-02-03
PT2629610T (pt) 2010-07-27 2017-11-24 Flex Pharma Inc Métodos e composições para prevenção e alívio de cãibras musculares e para recuperação de irritabilidade e fadiga neuromuscular após exercício
WO2012061160A1 (en) 2010-10-25 2012-05-10 Nexisvision, Inc. Methods and apparatus to identify eye coverings for vision
EP2646107A2 (en) 2010-12-01 2013-10-09 Spinal Modulation Inc. Agent delivery systems for selective neuromodulation
WO2014210186A2 (en) 2013-06-26 2014-12-31 Nexisvision, Inc. Contact lenses for refractive correction
US12044905B2 (en) 2011-04-28 2024-07-23 Journey1 Inc Contact lenses for refractive correction
US9423632B2 (en) 2012-04-20 2016-08-23 Nexisvision, Inc. Contact lenses for refractive correction
JP2014514613A (ja) 2011-04-28 2014-06-19 ネクシスビジョン， インコーポレイテッド 涙流、快適性、および／または適用性が改善された、眼被覆物および屈折矯正法および装置
US8678584B2 (en) 2012-04-20 2014-03-25 Nexisvision, Inc. Contact lenses for refractive correction
US8889659B2 (en) 2011-09-09 2014-11-18 Api Genesis, Llc Pain relief compositions, manufacture and uses
US9211274B2 (en) * 2012-02-01 2015-12-15 Warsaw Orthopedic, Inc. TRPV1 compounds in a biodegradable polymer carrier
US9465233B2 (en) 2012-04-20 2016-10-11 Nexisvision, Inc. Bimodular contact lenses
AU2013341380B2 (en) 2012-11-12 2018-04-26 Propella Therapeutics, Inc. Aqueous based capsaicinoid formulations, and treatment in combination with a corticosteroid
US9956166B2 (en) 2013-09-18 2018-05-01 Sorrento Therapeutics, Inc. Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin
US20150133561A1 (en) 2013-11-12 2015-05-14 Vizuri Health Sciences Llc Aqueous based capsaicinoid formulations and methods of manufacture and use
US9341864B2 (en) 2013-11-15 2016-05-17 Nexisvision, Inc. Contact lenses having a reinforcing scaffold
WO2015116559A1 (en) 2014-01-29 2015-08-06 Nexisvision, Inc. Multifocal bimodulus contact lenses
WO2015160941A1 (en) 2014-04-15 2015-10-22 Vizuri Health Sciences Llc Topical compositions for pain relief, manufacture and use
US9359316B1 (en) 2014-11-25 2016-06-07 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
US11634384B2 (en) 2014-11-25 2023-04-25 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
CN109562281B (zh) 2016-05-25 2021-12-17 同心镇痛药物公司 酚类trpv1激动剂的前药与局部麻醉药和血管收缩剂联合用于改善局部麻醉
CN110035740B (zh) 2016-11-02 2023-08-04 中枢疗法公司 稳定的水性辣椒素可注射制剂及其医学用途
US11253493B2 (en) 2017-01-23 2022-02-22 Cliff-Cartwright Corporation Compositions and methods affecting exercise performance
BR112020000989A2 (pt) 2017-07-20 2020-07-14 Centrexion Therapeutics Corporation métodos e composições para tratamento de dor com o uso de capsaicina
WO2020008261A2 (en) * 2018-07-05 2020-01-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods and compositions for treating pain and itch
CA3107433A1 (en) 2018-07-27 2020-01-30 Concentric Analgesics, Inc. Pegylated prodrugs of phenolic trpv1 agonists
US20210315846A1 (en) 2018-08-24 2021-10-14 Centrexion Therspeuties Corporation Capsaicin sequential dosing method for treatment of knee joint pain
US11447444B1 (en) 2019-01-18 2022-09-20 Centrexion Therapeutics Corporation Capsaicinoid prodrug compounds and their use in treating medical conditions
US11254659B1 (en) 2019-01-18 2022-02-22 Centrexion Therapeutics Corporation Capsaicinoid prodrug compounds and their use in treating medical conditions
US11357727B1 (en) 2021-01-22 2022-06-14 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11278494B1 (en) 2021-01-22 2022-03-22 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11033495B1 (en) 2021-01-22 2021-06-15 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
CN117883414B (zh) * 2024-03-18 2024-06-21 山东第二医科大学 一种长效缓释辣椒素微球及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4313958A (en) * 1980-10-24 1982-02-02 The Procter & Gamble Company Method of producing analgesia
US4424205A (en) * 1982-03-18 1984-01-03 The Procter & Gamble Company Hydroxyphenylacetamides having analgesic and anti-irritant activity
US4681897A (en) † 1984-01-16 1987-07-21 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
US4939149A (en) * 1988-10-24 1990-07-03 The United States Of America As Represented By The Department Of Health And Human Services Resiniferatoxin and analogues thereof to cause sensory afferent C-fiber and thermoregulatory desensitization
US5008289A (en) * 1988-12-02 1991-04-16 Galenpharma, Inc. Composition for treating nasal disorders and headaches
US4997853A (en) * 1988-12-02 1991-03-05 Galenpharma, Inc. Method and compositions utilizing capsaicin as an external analgesic
US5188837A (en) * 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5762963A (en) * 1995-06-07 1998-06-09 Emory University Method and compositions for controlling oral and pharyngeal pain using capsaicinoids

Also Published As

Publication number Publication date
CA2285203A1 (en) 1998-09-17
ES2350755T3 (es) 2011-01-26
DK0998288T3 (da) 2002-10-14
DK1201241T3 (da) 2010-12-13
EP0998288B1 (en) 2002-06-26
DE69841907D1 (de) 2010-11-04
CA2285203C (en) 2005-07-26
EP0998288B2 (en) 2005-08-03
JP2001515492A (ja) 2001-09-18
EP0998288A1 (en) 2000-05-10
DK0998288T4 (da) 2005-08-22
EP1201241A3 (en) 2004-01-02
HK1027759A1 (en) 2001-01-23
EP1201241B1 (en) 2010-09-22
EP1201241B8 (en) 2010-10-27
WO1998040070A1 (en) 1998-09-17
EP1201241A2 (en) 2002-05-02
AU6553298A (en) 1998-09-29
ES2179473T5 (es) 2006-03-01
AU720859B2 (en) 2000-06-15
PT1201241E (pt) 2010-12-02
ATE481970T1 (de) 2010-10-15
DE69806246D1 (de) 2002-08-01
DE69806246T2 (de) 2003-02-06
ATE219674T1 (de) 2002-07-15
US5962532A (en) 1999-10-05
DE69806246T3 (de) 2006-05-18
PT998288E (pt) 2002-11-29

Similar Documents

Publication Publication Date Title
ES2179473T3 (es) Composiciones que contienen capsaicina o analogos de capsaicina y un anestesico local.
DK1316308T3 (da) Transdermalt terapeutisk plaster med capsaicin og capsaicin-analoger
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
NL300382I1 (nl) Treatment of pompe's disease
ATE322280T1 (de) Verwendung von daptomycin
BR9812484A (pt) Terapia combinada para erradicação de hcv-rna detectável em pacientes com infecção crÈnica por hepatite c
NO305581B1 (no) Anvendelse av et benaktivt fosfonat i kombinasjon med et °strogenhormon, og preparat i enhetsdoseform for behandling av osteoporose
DE69229442D1 (de) Substituierte dibenzooxazepin-verbindungen, pharmazeutische zusammensetzungen und verfahren zur verwendung
ES2106531T3 (es) Compuestos de dibenzoxazepina substituidos en 2, 3, 4, 5, 6, 7, 8, 9 y/o 10, composiciones farmaceuticas y metodos de uso.
KR890003390A (ko) 골다공증 및 관련된 장해의 치료방법
ES2136167T3 (es) Composiciones de idebenona para tratar la enfermedad de alzheimer.
MX9300204A (es) Composicion farmaceutica que contiene azauridina para el tratamiento de la artritis reumatoide.
ATE200617T1 (de) Pharmazeutische zusammensetzungen zur transdermalen verabreichung von melatonin und/oder seine analoge
ATE126061T1 (de) Verwendung von lithium zur behandlung oder prophylaxe von molluscum contagiusum.
DK0434989T3 (da) Fremgangsmåde til forbedring af ventilationen under søvn og til behandling af søvnrelaterede ventilationsabnormaliteter
DE69927599D1 (de) Verwendung von wachstumshormon und analoga davon für die behandlung von säugern mit familiärer hypercholesterolämie
DE69218544D1 (de) Verwendung von BMY 14802 zur Behandlung von Angstzuständen bei Patienten mit Benzodiazepin-Entzugserscheinungen